Business
Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
HAYWARD, Calif., May 06, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers.
About this update from Arcus Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting","length":281,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall","length":196,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025","length":182,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Arcus is well positioned to advance its full pipeline with $1.0 billion in cash, cash equivalents and marketable securities at quarter end","length":138,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":797,"olType":false},{"type":"text","content":"HAYWARD, Calif., May 06, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers.","length":422,"tagName":"p"},{"type":"text","content":""Beginning with an oral presentation at ASCO for casdatifan in ccRCC, we expect to report a steady stream of data from ARC-20 throughout the remainder of 2025 and into 2026. We believe these data will support our robust development plan for casdatifan across multiple settings. This includes our Phase 3 trial, PEAK-1 in the IO-experienced setting, our clinical trial with AstraZeneca, which will combine casdatifan with their anti-PD-1/CTLA-4 bispecific antibody in the IO-naive setting, and three new cohorts in ARC-20 evaluating casdatifan in first- and second-line ccRCC," said Terry Rosen, Ph.D., chief executive officer of Arcus. "We believe that casdatifan has the pot...